Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors

Trial Profile

Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Pexidartinib (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Plexxikon
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Jul 2019 to 1 Jul 2018.
    • 26 Jul 2017 Planned primary completion date changed from 1 May 2019 to 1 May 2018.
    • 26 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top